Anthropic's long shadow
1. Key Themes
Theme: Anthropic's IPO will reset how private AI companies are valued and scrutinized
Public price discovery replaces opaque private-market valuation
Private investors have lacked a clean way to price frontier AI labs, and a public listing by the category leader changes that.
"For years, the private market has had little clarity on how to price the AI companies now riding a wave of unprecedented growth. And for better or worse, Anthropic is about to change all of that with its Wall Street debut coming in November." "Daily, real-time data and regular financial reporting by a market leader will set a new standard, despite economics that are still untested."
Transparency raises the bar for every other AI company
Public data cuts both ways, and the investor audience widens dramatically.
"On the other hand, the sudden unleashing of publicly available data and analysis also raises the stakes, putting pressure on the AI companies to keep up. Expectations will be much higher, and they will come from a vastly larger contingent: the broader investing public."
Theme: Biopharma exits have reopened, driven by M&A and the patent cliff
Exit value is surging versus 2025
"Q3's $15.3 billion in exit value is the second-highest quarterly total since 2022. And with a quarter still to go, 2026 has already logged 1.8x the exit value of all of 2025."
M&A, not IPOs, is the main liquidity channel, at record prices
"Even as a reopened IPO window produced back-to-back record offerings, M&A is still doing the heavy lifting, accounting for 63% of the 2026." "Big Pharma is paying up for VC-backed companies: The median acquisition value has climbed to nearly $820 million, the highest in our dataset."
The patent cliff is the demand driver, with specific buyer strategies
"That appetite stems from the looming patent cliff, which puts hundreds of billions in revenue at risk as blockbuster drugs lose exclusivity." "Instead, pharma is racing to own the next generation of cell therapy, while Eli Lilly is diversifying its portfolio using their GLP-1 windfall."
Early warning signs of a wobble
"But there are signs of a wobble, as acquisition activity slowed in Q3, and public biotech indices slipped from August highs."
Theme: Venture secondaries are concentrated in AI and data, with interest broadening
Secondary volume skews heavily to AI/data and recently funded companies
"AI and data companies dominate venture secondaries, with 90% of annualized volume on Caplight tied to data, AI, or startups that recently closed a primary or secondary round."
Investor appetite is widening to other sectors
"Broker Rainmaker Securities says investor interest is widening to established fintech, defense, and prediction market players."
Theme: AI-for-industry startups are attracting large early-stage checks
Vertical AI applications span engineering, minerals, waste, and industrial control
"Dulo, a startup co-founded by Sebastian Thrun developing AI models for engineering, raised a $130 million seed round from investors including former Google CEO Eric Schmidt, Kleiner Perkins' John Doerr and DST Global." "Singapore-based Oxus Metals AI, which develops AI for discovering critical minerals, raised a $36 million round at a $180 million valuation." "TrashLab, the developer of an AI operating system for waste services, secured a $12 million round led by Ventana." "Neuron Industries, a startup building an industrial control AI system, raised a $10 million seed round led by FCVC and Obvious Ventures."
2. Contrarian Perspectives
Contrarian view: An IPO may be a net negative for the AI ecosystem, not just a clean pricing event. Most would assume public-market transparency is simply good for valuation clarity. The newsletter notes that it also exposes unproven economics and raises expectations for peers.
"Daily, real-time data and regular financial reporting by a market leader will set a new standard, despite economics that are still untested." "Expectations will be much higher, and they will come from a vastly larger contingent: the broader investing public."
Contrarian view: Big Pharma's M&A binge does not address the problem motivating it. The patent cliff is a near-term revenue problem, yet the acquired assets are years from revenue.
"But VC-backed biotechs are typically years from generating revenue, so they do little to fill that near-term gap."
3. Companies Identified
Anthropic
- Description: Frontier AI lab preparing a public listing.
- Why mentioned: Its IPO will set a pricing and disclosure benchmark for private AI companies.
- Quote: "Anthropic is about to change all of that with its Wall Street debut coming in November."
- Description: Startup developing AI models for engineering, co-founded by Sebastian Thrun.
- Why mentioned: Raised an outsized $130M seed round with marquee investors.
- Quote: "raised a $130 million seed round from investors including former Google CEO Eric Schmidt, Kleiner Perkins' John Doerr and DST Global"
- Description: Israel-based cybersecurity startup.
- Why mentioned: In talks for a new round at a $20B valuation.
- Quote: "is in talks to raise a new round at a $20 billion valuation, The Information reported."
- Description: Biotech developing treatments for severe rare diseases.
- Why mentioned: $90M Series A.
- Quote: "secured a $90 million Series A from investors including Deerfield Management, Canaan and Droia Ventures."
- Description: Singapore-based AI for critical mineral discovery.
- Why mentioned: $36M raise at a $180M valuation.
- Quote: "raised a $36 million round at a $180 million valuation."
TrashLab
- Description: AI operating system for waste services.
- Why mentioned: $12M round led by Ventana.
- Quote: "secured a $12 million round led by Ventana."
Neuron Industries
- Description: Industrial control AI system developer.
- Why mentioned: $10M seed round.
- Quote: "raised a $10 million seed round led by FCVC and Obvious Ventures."
OPay
- Description: SoftBank-backed Nigerian payments company.
- Why mentioned: US IPO exit.
- Quote: "raised $304 million in its US IPO."
Bambusa Therapeutics
- Description: RA Capital-backed biotech for immunological and inflammatory conditions.
- Why mentioned: IPO exit.
- Quote: "raised $168.9 million in its IPO."
Aspen Neuroscience
- Description: OrbiMed-backed neurodegenerative disease biotech.
- Why mentioned: IPO exit.
- Quote: "raised $140.6 million in its IPO."
Binance
- Description: Crypto exchange operator.
- Why mentioned: Suffered a massive security breach.
- Quote: "was hit by a security breach that compromised about $6.3 billion in assets held in users' crypto wallets."
7 Brew
- Description: Fast-growing coffee chain backed by Blackstone.
- Why mentioned: Gaining share from incumbents via social media trends.
- Quote: "Helped along by TikTok trends, 7 Brew is rapidly expanding and taking bites out of Starbucks, Dunkin' and Dutch Bros in the US coffee market."
Eli Lilly
- Description: Pharma major with a GLP-1 windfall.
- Why mentioned: Using GLP-1 profits to diversify via acquisitions.
- Quote: "Eli Lilly is diversifying its portfolio using their GLP-1 windfall."
Caplight / Rainmaker Securities
- Description: Secondary-market data platform and broker.
- Why mentioned: Sources for secondary market trends.
- Quote: "Broker Rainmaker Securities says investor interest is widening to established fintech, defense, and prediction market players."
4. People Identified
Sebastian Thrun
- Description: Co-founder of Dulo.
- Why mentioned: Leading a new AI-for-engineering startup with a $130M seed.
- Quote: "a startup co-founded by Sebastian Thrun developing AI models for engineering"
Eric Schmidt
- Description: Former Google CEO.
- Why mentioned: Investor in Dulo's seed round.
- Quote: "investors including former Google CEO Eric Schmidt"
John Doerr
- Description: Investor at Kleiner Perkins.
- Why mentioned: Investor in Dulo's seed round.
- Quote: "Kleiner Perkins' John Doerr and DST Global"
Alexander Davis
- Description: Head of Enterprise Reporting at PitchBook.
- Why mentioned: Author of the Anthropic IPO analysis.
- Quote: "By Alexander Davis, Head of Enterprise Reporting"
Ben Zercher
- Description: Senior Research Analyst, Biotech & Pharma at PitchBook.
- Why mentioned: Author of the biopharma exits analysis.
- Quote: "By Ben Zercher, Senior Research Analyst, Biotech & Pharma"
5. Operating Insights
Expect public-market scrutiny to set the bar for AI company disclosure
Founders in AI should anticipate that Anthropic's reporting becomes the benchmark investors compare them against.
"Daily, real-time data and regular financial reporting by a market leader will set a new standard."
Biotech founders: pitch to the strategic buyer's specific gap
Acquirers are buying in defined areas such as cell therapy rather than broadly.
"Pharma is racing to own the next generation of cell therapy, while Eli Lilly is diversifying its portfolio using their GLP-1 windfall."
Secondary liquidity favors companies with fresh primary rounds and AI/data positioning
Companies seeking secondary liquidity should keep their primary round recency and sector story strong.
"90% of annualized volume on Caplight tied to data, AI, or startups that recently closed a primary or secondary round."
6. Overlooked Insights
Cyber risk at crypto infrastructure scale, with state-actor attribution
The Binance incident is framed in the side letters as the biggest crypto heist ever, and attribution to North Korea suggests nation-state threat levels that may matter for custody and security investing.
"Starting last Thursday evening, hackers siphoned about $6.3 billion across Binance wallets—and multiple firms think those responsible are from North Korea."
Autonomous mining trucks are proving out in extreme environments
A brief mention points to robust industrial autonomy, adjacent to the critical-minerals AI theme.
"The vehicles can operate in some of the world's harshest conditions, from cold Mongolian winters to 110-degree heat in Western Australia."